Katarina Mišura has been awarded the prestigious Fellinger Krebsforschung grant, a significant recognition of her promising work in cancer research.

My doctoral research focuses on drug-tolerant persister cells (DTPs) and drug resistance mechanisms in ALK+ anaplastic large cell lymphoma (ALCL) and other ALK+ malignancies, such as non-small cell lung cancer (NSCLC).

During my studies, I was especially drawn to biomarker discovery, focusing my Master’s thesis on investigating gene polymorphisms to improve cardiovascular drug safety.

During my studies, I was especially drawn to biomarker discovery, focusing my Master’s thesis on investigating gene polymorphisms to improve cardiovascular drug safety.

To really understand how diseases form, I realised I needed to study the human body in depth, at cellular and molecular level.

During my master’s thesis, I investigated the WIP1/PPM1D phosphatase oncoprotein as a therapeutic target for potentiating p53-dependent therapies.

I’m particularly fascinated by how metabolic changes contribute to the transformation of normal T cells into malignant ones in ALCL. My current project dives into the role of STAT proteins

I started my science journey a few years ago with a Bachelor Degree in Biological Sciences at Eastern Piedmont University

My project focuses on uncovering and validating non-mutational mechanisms of resistance to ALK inhibitors in ALK-positive ALCL. While targeted therapies like ALK inhibitors have significantly improved patient outcomes, treatment resistance remains a major obstacle to long-term success.

Today, I’m a proud Marie Skłodowska-Curie Fellow under the EU Horizon Europe program—a fellowship that supports my work and enables international collaboration.